U of T hypothalamic pituitary dysfunction


U of T Libraries U of T Home Portal ROSI Campus Maps
University of TorontoTSpace
Browse
Help
Search
About
First time users
Login
TSpace Repository University of Toronto Scarborough Bioline International Journal of Postgraduate Medicine
Title:
Characterization of adult onset growth hormone deficiency syndrome in patients with hypothalamopituitary diseases: Asian Indian data
Author:
TR Bandgar; M Prashanth; SR Joshi; PS Menon; NS Shah
Issue Date:
2-Jan-2008
Publisher:
Medknow Publications and Staff Society of Seth GS Medical College and KEM Hospital, Mumbai, India
Description:
Background: Hardly any data is available on Adult onset growth hormone deficiency (AOGHD) in Patients with hypothalamopituitary diseases in India. Aims: To characterize Asian Indian AOGHD syndrome in hypothalamopituitary diseases. Settings and Design: Cross-sectional analysis of data from a tertiary care hospital. Materials and Methods: Thirty patients with AOGHD were compared with 30 age-, sex-, body mass index-matched controls with respect to endocrine evaluation, biochemistry, body composition (BC), bone mineral density (BMD), cardiovascular risk profile and quality of life (QoL). Statistical Analysis Used: Comparisons were performed using two-tailed Student′s test (SPSS Software version 10.0). Results: Most of the patients had abnormal BC with central obesity [Truncal FM (%): males {33.9±4.4 (patient) vs. 29.31±6.2 (control); P -0.027}; females {39.87±5.93 (patient) vs. 35.76±3.16 (control); P – 0.025}] and poor QoL. Patients aged over 45 years did not show low bone mass or lipid abnormalities as compared to controls. Low BMD and abnormal lipid profile {Triglycerides [mg/dl]:170.55±72.5 (patient) vs101.24±31.0 (control); P -0.038}; {very low density lipoprotein cholesterol [mg/dl]: 33.54±14.9 (patient) vs. 20.25±6.18 (control); P – 0.05} was seen in female patients less than 45 years of age. Conclusions: Male and female (more than 45 years) AOGHD patients have increased cardiovascular risk factors and poor QoL while BMD is unaffected. Females less than 45 years of age have the major characteristics of AOGHD and would be the group to benefit maximally with recombinant human Growth Hormone treatment, which is similar to that in the western literature.

Advertisements

About garyskeete

ASHWORTH MEDICINE-Professional Medical Assisting, Doctor of Science,Legal Assistant Diploma BSc Criminal Justice
This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s